Engineering and characterization of a novel PD-L1/VEGF bispecific antibody with enhanced VEGF-neutralizing capacity
Biochemical and Biophysical Research Communications · 2026-08 · 828 · 154136
DOI: 10.1016/j.bbrc.2026.154136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026-08. Verfasst von Qiaoshuang Chen und 20 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences, Cixi Biomedical Research Institute, Wenz…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Vascular Endothelial Growth Factor A, B7-H1 Antigen, Protein Engineering. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Wenzhou Medical University, Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Combined blockade of PD-L1 and VEGF represents a promising therapeutic strategy for cancer, yet enhancing anti-VEGF efficacy remains challenging. Here, we engineered a novel bispecific antibody, PLVBP, by fusing a novel high-affinity anti-PD-L1 antibody (T0004) with four VEGF binding domains derived from VEGFR1 D2 (domain II). PLVBP was efficiently expressed in mammalian cells and purified via a three-step chromatography process, achieving over 98% purity. Comprehensive structural characterization confirmed its homogeneity, stability, and preserved secondary structure. Surface plasmon resonance (SPR) analysis revealed that PLVBP binds to PD-L1 and VEGF165 with sub-nanomolar affinities. Functional assays demonstrated that PLVBP maintained potent PD-L1 binding while exhibiting significantly enhanced VEGF binding affinity and capacity compared to bevacizumab. Furthermore, in cell-based assays, PLVBP effectively suppressed VEGF-induced HUVEC proliferation and migration, confirming its VEGF-neutralizing activity. Furthermore, PLVBP simultaneously engaged both PD-L1 and VEGF, validating its dual-targeting capability. Preliminary stability assessments indicated that PLVBP largely maintained its physicochemical and functional integrity during long-term storage in non-optimized buffer. These findings highlight PLVBP as a promising bispecific therapeutic candidate with enhanced avidity-driven VEGF capture, providing a strong foundation for further preclinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences, Cixi Biomedical Research Institute, Wenzhou Medical University, Wenzhou, China; State Key Laboratory of Macrom…
Förderung
- National Natural Science Foundation of China
- Wenzhou Medical University
- Shandong Province Natural Science Foundation
- Liaocheng University
Zitieren
APA
Chen, Q., Hang, T., Mao, D., Zhou, A., Xu, J., Liu, T., Zheng, C., Zhang, X., Guo, Q., Ji, L., Qian, W., Hou, S., Li, J., Han, F., Wang, X., Zhang, X., Guo, Y., Zhang, D., Li, J., …, & Sun, Z. (2026). Engineering and characterization of a novel PD-L1/VEGF bispecific antibody with enhanced VEGF-neutralizing capacity. Biochemical and Biophysical Research Communications, 828, 154136. https://doi.org/10.1016/j.bbrc.2026.154136
Vancouver
Chen Q, Hang T, Mao D, Zhou A, Xu J, Liu T, et al. Engineering and characterization of a novel PD-L1/VEGF bispecific antibody with enhanced VEGF-neutralizing capacity. Biochemical and Biophysical Research Communications. 2026;828:154136. doi:10.1016/j.bbrc.2026.154136
BibTeX
@article{Chen2026,
author = {Chen, Qiaoshuang and Hang, Tongyu and Mao, Dan and Zhou, Anqi and Xu, Jin and Liu, Tao and Zheng, Chunguang and Zhang, Xinyu and Guo, Qingcheng and Ji, Lusha and Qian, Weizhu and Hou, Sheng and Li, Jun and Han, Fubo and Wang, Xuekun and Zhang, Xin and Guo, Yajun and Zhang, Dapeng and Li, Jing and Guo, Huaizu and Sun, Ziqiao},
title = {Engineering and characterization of a novel PD-L1/VEGF bispecific antibody with enhanced VEGF-neutralizing capacity},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
volume = {828},
pages = {154136},
doi = {10.1016/j.bbrc.2026.154136}
}
EUVIMED